Single peptide Vial strength 10 mg
Selank10 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
Selank, explained simply
A heptapeptide evaluated in human studies, chiefly through the intranasal route in neuropsychiatric research settings.
Research area
Neuroscience and mood
How it works
Selank is a synthetic heptapeptide derived from the tuftsin sequence, studied mainly by the intranasal route.
Why it matters
It is of interest in research on anxiety and neurobiological signaling.
What has been observed
Human studies in neurological and anxiety-related settings are cited separately from vial calculations.
Effects and points to consider
The intranasal formulation and delivery device are essential for interpreting amounts; clinical evidence remains specific to the studied settings.
01 / Vial strength 10 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 10 mg Selank |
|---|---|
| 5 mL final volume | 2 mg/mL 200 mcg per verified 0.10 mL spray, and 50 nominal sprays. |
| 10 mL final volume | 1 mg/mL 100 mcg per verified 0.10 mL spray, and 100 nominal sprays. |
| Primary human research route | Intranasal drops or measured intranasal solution. |
Selank 10 mg Nasal Spray Calculations
| Measured Final Volume | Vehicle Added After Transfer | Final Concentration | Per Verified 0.10 mL Spray |
|---|---|---|---|
| 5.0 mL | About 2.0 mL | 2,000 mcg/mL | 200 mcg 50 nominal sprays |
| 10.0 mL | About 7.0 mL | 1,000 mcg/mL | 100 mcg 100 nominal sprays |
| 6.67 mL (registered-product concentration reference) | About 3.67 mL | 1,500 mcg/mL | 150 mcg 66.7 nominal sprays |
Reference Schedule
| Period | Amount | Spray Volume | Frequency |
|---|---|---|---|
| Days 1–14 | 300 mcg per administration (900 mcg/day) | 0.20 mL at 1.5 mg/mL (2 verified 0.10 mL sprays) | 3 times daily |
Mathematical Actuator Equivalents
| Literature Amount | 5 mL Option200 mcg per Spray | 10 mL Option100 mcg per Spray |
|---|---|---|
| 300 mcg | 1.5 theoretical sprays | 3 sprays |
| 900 mcg | 4.5 theoretical sprays | 9 sprays |
| 2,700 mcg | 13.5 theoretical sprays | 27 sprays |
Published Human Intranasal Selank Research
| Source | Research Context | Published Intranasal Amount and Formulation |
|---|---|---|
| Zozulia et al., 2008[1] | 62 adults with generalized anxiety disorder or neurasthenia | Selank 0.15% nasal drops at 2.7 mg per day, reported as 36 drops divided across three administrations, with outcomes followed through day 14. |
| Syunyakov et al., 2012[2] | 20 adults with generalized anxiety disorder | 2,700 mcg per day intranasally. The pharmaco-EEG analysis also examined a single 900 mcg exposure. |
| Panikratova et al., 2020[4] | Healthy-volunteer functional connectivity study | One intranasal exposure using 0.15% Selank solution, 60 microliters per nostril, described as a 0.2 mg total amount. |
Core Formula
| Verified Actuator Output | 5 mL Option2,000 mcg/mL | 10 mL Option1,000 mcg/mL |
|---|---|---|
| 0.05 mL | 100 mcg | 50 mcg |
| 0.10 mL | 200 mcg | 100 mcg |
| 0.13 mL | 260 mcg | 130 mcg |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.